Gilead HIV Combo Beats Glaxo Drug in Trial

NEW YORK (Reuters) - Gilead Sciences on Thursday said preliminary data from a 48-week trial show that two of its two drugs, Viread and Emtriva, were better able to control levels of HIV than Combivir, a popular treatment sold by GlaxoSmithKline Plc.

Continue to Gilead HIV Combo Beats Glaxo Drug in Trial on Reuters: Health.

Medical Buzz delivers the most recent headlines from the medical world. Diseases, cures, accidents, medicin. Click below for more headlines ...
Medical buzz